Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus ...

Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus ...